

Michael Lim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7431199/publications.pdf>

Version: 2024-02-01

328
papers

19,807
citations

22153

59
h-index

13771

129
g-index

332
all docs

332
docs citations

332
times ranked

24583
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	12.4	3,665
2	Current state of immunotherapy for glioblastoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 422-442.	27.6	873
3	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1003.	7.1	805
4	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	10.7	776
5	Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 343-349.	0.8	757
6	Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. <i>Lancet Oncology</i> , The, 2015, 16, e498-e509.	10.7	660
7	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.2	543
8	Mechanisms of immunotherapy resistance: lessons from glioblastoma. <i>Nature Immunology</i> , 2019, 20, 1100-1109.	14.5	421
9	Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 113-122.	1.2	400
10	Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology</i> , 2018, 20, 674-686.	1.2	364
11	Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. <i>Clinical Cancer Research</i> , 2017, 23, 124-136.	7.0	345
12	Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9704-9709.	7.1	317
13	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015, 11, 504-514.	10.1	307
14	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 916-925.	0.8	257
15	Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. <i>Science Translational Medicine</i> , 2016, 8, 370ra180.	12.4	243
16	Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E10981-E10990.	7.1	217
17	TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. <i>Oncotarget</i> , 2018, 7, e1466769.	4.6	217
18	Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. <i>Nature Biomedical Engineering</i> , 2018, 2, 850-864.	22.5	214

#	ARTICLE	IF	CITATIONS
19	Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model. <i>PLoS ONE</i> , 2014, 9, e101764.	2.5	206
20	Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 1119-1128.	3.4	181
21	Multiple resections for patients with glioblastoma: prolonging survival. <i>Journal of Neurosurgery</i> , 2013, 118, 812-820.	1.6	166
22	Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter. <i>Neuro-Oncology</i> , 2022, 24, 1935-1949.	1.2	165
23	A review of glioblastoma immunotherapy. <i>Journal of Neuro-Oncology</i> , 2021, 151, 41-53.	2.9	159
24	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. <i>Neuro-Oncology</i> , 2023, 25, 123-134.	1.2	150
25	Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?. <i>Future Oncology</i> , 2014, 10, 1277-1297.	2.4	143
26	Next-generation sequencing in neuropathologic diagnosis of infections of the nervous system. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e251.	6.0	142
27	Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. <i>Biomaterials</i> , 2021, 266, 120431.	11.4	131
28	Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites. <i>Frontiers in Oncology</i> , 2015, 5, 153.	2.8	129
29	Carboxylated branched poly(β -amino ester) nanoparticles enable robust cytosolic protein delivery and CRISPR-Cas9 gene editing. <i>Science Advances</i> , 2019, 5, eaay3255.	10.3	127
30	Increased Subventricular Zone Radiation Dose Correlates With Survival in Glioblastoma Patients After Gross Total Resection. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 616-622.	0.8	121
31	Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-20.	3.3	119
32	Targeting cytokines for treatment of neuropathic pain. <i>Scandinavian Journal of Pain</i> , 2017, 17, 287-293.	1.3	118
33	Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-Naïve Prostate Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 3394-3401.	7.0	117
34	Radiosurgery of Glomus Jugulare Tumors: A Meta-Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e497-e502.	0.8	107
35	Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy. <i>Clinical Cancer Research</i> , 2019, 25, 552-561.	7.0	104
36	Distinguishing True Progression From Radionecrosis After Stereotactic Radiation Therapy for Brain Metastases With Machine Learning and Radiomics. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1236-1243.	0.8	103

#	ARTICLE	IF	CITATIONS
37	Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma. <i>International Journal of Cancer</i> , 2018, 143, 3201-3208.	5.1	101
38	STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications. <i>Cancers</i> , 2014, 6, 376-395.	3.7	97
39	Immunotherapy for Brain Cancer: Recent Progress and Future Promise. <i>Clinical Cancer Research</i> , 2014, 20, 3651-3659.	7.0	92
40	Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment. <i>Journal of Neuro-Oncology</i> , 2019, 143, 241-249.	2.9	88
41	Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. <i>International Journal of Cancer</i> , 2016, 138, 187-194.	5.1	83
42	Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas. <i>European Journal of Cancer</i> , 2017, 83, 9-18.	2.8	82
43	CyberKnife radiosurgery for idiopathic trigeminal neuralgia. <i>Neurosurgical Focus</i> , 2005, 18, 1-7.	2.3	81
44	Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 3575-3584.	7.0	78
45	The role of regulatory T-cells in glioma immunology. <i>Clinical Neurology and Neurosurgery</i> , 2014, 119, 125-132.	1.4	76
46	ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. <i>Theranostics</i> , 2020, 10, 5943-5956.	10.0	76
47	Invasive adenoma and pituitary carcinoma: a SEER database analysis. <i>Neurosurgical Review</i> , 2014, 37, 279-286.	2.4	74
48	Pituitary adenomas: historical perspective, surgical management and future directions. <i>CNS Oncology</i> , 2015, 4, 411-429.	3.0	73
49	Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. <i>Genome Biology</i> , 2020, 21, 216.	8.8	73
50	Deep venous thrombosis and pulmonary embolisms in adult patients undergoing craniotomy for brain tumors. <i>Neurological Research</i> , 2013, 35, 206-211.	1.3	70
51	Seizure Control for Patients Undergoing Meningioma Surgery. <i>World Neurosurgery</i> , 2013, 79, 515-524.	1.3	69
52	Metastatic Atypical and Anaplastic Meningioma: A Case Series and Review of the Literature. <i>World Neurosurgery</i> , 2017, 101, 47-56.	1.3	69
53	Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. <i>Current Treatment Options in Oncology</i> , 2017, 18, 51.	3.0	69
54	Mechanisms of Local Immuno-resistance in Glioma. <i>Neurosurgery Clinics of North America</i> , 2010, 21, 17-29.	1.7	67

#	ARTICLE	IF	CITATIONS
55	Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses. <i>BioMed Research International</i> , 2013, 2013, 1-8.	1.9	66
56	A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials. <i>Cancers</i> , 2019, 11, 537.	3.7	66
57	Current Vaccine Trials in Glioblastoma: A Review. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	2.2	65
58	Subependymoma: clinical features and surgical outcomes. <i>Neurological Research</i> , 2012, 34, 677-684.	1.3	64
59	Adult Cranioplasty Reconstruction With Customized Cranial Implants: Preferred Technique, Timing, and Biomaterials. <i>Journal of Craniofacial Surgery</i> , 2018, 29, 887-894.	0.7	64
60	Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma. <i>Oncotarget</i> , 2018, 9, 20681-20697.	1.8	63
61	The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy. <i>Cancers</i> , 2014, 6, 1953-1985.	3.7	62
62	TLR9 Is Critical for Glioma Stem Cell Maintenance and Targeting. <i>Cancer Research</i> , 2014, 74, 5218-5228.	0.9	60
63	Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021, 23, 356-375.	1.2	59
64	Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. <i>Clinical Cancer Research</i> , 2016, 22, 1161-1172.	7.0	57
65	PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. <i>Journal of Neuro-Oncology</i> , 2015, 121, 251-259.	2.9	56
66	The role of STAT3 activation in modulating the immune microenvironment of GBM. <i>Journal of Neuro-Oncology</i> , 2012, 110, 359-368.	2.9	54
67	Influence of insurance status on survival of adults with glioblastoma multiforme: A population-based study. <i>Cancer</i> , 2016, 122, 3157-3165.	4.1	52
68	Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. , 2016, 4, 28.		52
69	Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. <i>Oncolmmunology</i> , 2018, 7, e1500108.	4.6	52
70	Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3010-3010.	1.6	52
71	Efficacy and safety of stereotactic radiosurgery for glomus jugulare tumors. <i>Neurosurgical Focus</i> , 2004, 17, 68-72.	2.3	51
72	A Phase 2 Study of Post-Operative Stereotactic Body Radiation Therapy (SBRT) for Solid Tumor Spine Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 261-268.	0.8	49

#	ARTICLE	IF	CITATIONS
73	Vessel Wall MRI for Targeting Biopsies of Intracranial Vasculitis. American Journal of Neuroradiology, 2018, 39, 2034-2036.	2.4	48
74	A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. Journal of Neuro-Oncology, 2020, 148, 419-431.	2.9	48
75	Predictors of Inpatient Death and Complications among Postoperative Elderly Patients with Metastatic Brain Tumors. Annals of Surgical Oncology, 2011, 18, 521-528.	1.5	46
76	Stereotactic Radiosurgery in the Management of Brain Metastases: An Institutional Retrospective Analysis of Survival. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1486-1492.	0.8	45
77	PD-L1 expression in medulloblastoma: an evaluation by subgroup. Oncotarget, 2018, 9, 19177-19191.	1.8	45
78	Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology, 2015, 29, 331-40.	0.5	45
79	Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.. Journal of Clinical Oncology, 2017, 35, 2042-2042.	1.6	44
80	Glycerol rhizotomy and radiofrequency thermocoagulation for trigeminal neuralgia in multiple sclerosis. Journal of Neurosurgery, 2013, 118, 329-336.	1.6	43
81	ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRVIII-EXPRESSING GLIOBLASTOMA. Neuro-Oncology, 2016, 18, vi17-vi18.	1.2	43
82	Immediate Single-Stage Cranioplasty Following Calvarial Resection for Benign and Malignant Skull Neoplasms Using Customized Craniofacial Implants. Journal of Craniofacial Surgery, 2015, 26, 1456-1462.	0.7	42
83	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
84	Roles of Neutrophils in Glioma and Brain Metastases. Frontiers in Immunology, 2021, 12, 701383.	4.8	41
85	A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.. Journal of Clinical Oncology, 2016, 34, TPS2079-TPS2079.	1.6	41
86	Radiosurgery for Glomus Jugulare Tumors. Technology in Cancer Research and Treatment, 2007, 6, 419-423.	1.9	40
87	The Radiosurgical Treatment of Arteriovenous Malformations: Obliteration, Morbidities, and Performance Status. International Journal of Radiation Oncology Biology Physics, 2011, 80, 354-361.	0.8	40
88	Î±5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth. Acta Neuropathologica, 2014, 127, 593-603.	7.7	39
89	Multi-institutional validation of a preoperative scoring system which predicts survival for patients with glioblastoma. Journal of Clinical Neuroscience, 2013, 20, 1422-1426.	1.5	38
90	Multidisciplinary Approach for Improved Outcomes in Secondary Cranial Reconstruction. Operative Neurosurgery, 2014, 10, 179-190.	0.8	38

#	ARTICLE	IF	CITATIONS
91	Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 1715.	4.8	38
92	Combination immunotherapy strategies for glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 151, 375-391.	2.9	38
93	Risk Factors for Preoperative Seizures and Loss of Seizure Control in Patients Undergoing Surgery for Metastatic Brain Tumors. <i>World Neurosurgery</i> , 2017, 104, 120-128.	1.3	37
94	The Relevance of Simpson Grade Resections in Modern Neurosurgical Treatment of World Health Organization Grade I, II, and III Meningiomas. <i>World Neurosurgery</i> , 2018, 109, e588-e593.	1.3	37
95	Efficacy of osimertinib against EGFRvIII+ glioblastoma. <i>Oncotarget</i> , 2020, 11, 2074-2082.	1.8	37
96	Immunotherapy for Glioma. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 357-370.	1.7	36
97	Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. <i>Journal of Immunology Research</i> , 2016, 2016, 1-14.	2.2	36
98	Radiosurgery for glomus jugulare: history and recent progress. <i>Neurosurgical Focus</i> , 2009, 27, E5.	2.3	35
99	The Transconjunctival Transorbital Approach: A Keyhole Approach to the Midline Anterior Skull Base. <i>World Neurosurgery</i> , 2013, 80, 864-871.	1.3	35
100	CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future. <i>Frontiers in Immunology</i> , 2022, 13, 817296.	4.8	35
101	The Efficacy of Linear Accelerator Stereotactic Radiosurgery in Treating Glomus Jugulare Tumors. <i>Technology in Cancer Research and Treatment</i> , 2003, 2, 261-265.	1.9	34
102	Reduced CSF leak in complete calvarial reconstructions of microvascular decompression craniectomies using calcium phosphate cement. <i>Journal of Neurosurgery</i> , 2015, 123, 1476-1479.	1.6	34
103	Factors associated with survival for patients with glioblastoma with poor pre-operative functional status. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 818-823.	1.5	33
104	Vaccine strategies for glioblastoma: progress and future directions. <i>Immunotherapy</i> , 2013, 5, 155-167.	2.0	33
105	Radiotherapy, Lymphopenia, and Host Immune Capacity in Glioblastoma: A Potentially Actionable Toxicity Associated With Reduced Efficacy of Radiotherapy. <i>Neurosurgery</i> , 2019, 85, 441-453.	1.1	33
106	Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2032-2032.	1.6	33
107	Î±vÎ²3 Integrin in central nervous system tumors. <i>Human Pathology</i> , 2005, 36, 665-669.	2.0	32
108	Endoscopic transvestibular paramandibular exploration of the infratemporal fossa and parapharyngeal space: A minimally invasive approach to the middle cranial base. <i>Laryngoscope</i> , 2011, 121, 2075-2080.	2.0	32

#	ARTICLE	IF	CITATIONS
109	Use of Stereotactic Radiosurgery in Elderly and Very Elderly Patients With Brain Metastases to Limit Toxicity Associated With Whole Brain Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 939-947.	0.8	32
110	Targeting DDX3 in Medulloblastoma Using the Small Molecule Inhibitor RK-33. <i>Translational Oncology</i> , 2019, 12, 96-105.	3.7	31
111	Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells. <i>Cancer Research</i> , 2021, 81, 2457-2469.	0.9	31
112	Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature. <i>Neurosurgical Review</i> , 2011, 34, 181-189.	2.4	29
113	Immunotherapy and radiation in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 134, 531-539.	2.9	29
114	Biomarkers and Immunotherapeutic Targets in Glioblastoma. <i>World Neurosurgery</i> , 2017, 102, 494-506.	1.3	29
115	Stereotactic radiosurgery using CT cisternography and non-isocentric planning for the treatment of trigeminal neuralgia. <i>Computer Aided Surgery</i> , 2006, 11, 11-20.	1.8	28
116	Transpalpebral Orbitofrontal Craniotomy: A Minimally Invasive Approach to Anterior Cranial Vault Lesions. <i>Skull Base</i> , 2010, 20, 237-244.	0.4	28
117	Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation. <i>Neurological Research</i> , 2015, 37, 717-726.	1.3	28
118	Irradiation of glomus jugulare tumors: a historical perspective. <i>Neurosurgical Focus</i> , 2007, 23, E12.	2.3	27
119	Surgical treatment of pediatric trigeminal neuralgia: case series and review of the literature. <i>Child's Nervous System</i> , 2011, 27, 2123-2129.	1.1	26
120	Immunomodulation: checkpoint blockade etc.: Fig. 1.. <i>Neuro-Oncology</i> , 2015, 17, vii26-vii31.	1.2	26
121	Prognostic factors associated with pain palliation after spine stereotactic body radiation therapy. <i>Journal of Neurosurgery: Spine</i> , 2015, 23, 620-629.	1.7	26
122	Absence of host NF- κ B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1491-1503.	4.2	26
123	Nelfinavir induces radiation sensitization in pituitary adenoma cells. <i>Cancer Biology and Therapy</i> , 2011, 12, 657-663.	3.4	25
124	Potential Role for STAT3 Inhibitors in Glioblastoma. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 379-389.	1.7	25
125	Factors associated with survival and recurrence for patients undergoing surgery of cerebellar metastases. <i>Neurological Research</i> , 2014, 36, 13-25.	1.3	25
126	Layered Sellar Reconstruction with Avascular Free Grafts: Acceptable Alternative to the Nasoseptal Flap for repair of Low-Volume Intraoperative Cerebrospinal Fluid Leak. <i>American Journal of Rhinology and Allergy</i> , 2016, 30, 367-371.	2.0	25

#	ARTICLE	IF	CITATIONS
127	The strategy of repeat stereotactic radiosurgery without whole brain radiation treatment for new brain metastases: Outcomes and implications for follow-up monitoring. <i>Practical Radiation Oncology</i> , 2016, 6, 409-416.	2.1	24
128	<i>BRAF</i> V600 mutational status affects recurrence patterns of melanoma brain metastasis. <i>International Journal of Cancer</i> , 2017, 140, 2716-2727.	5.1	24
129	Efficacy of primary microvascular decompression versus subsequent microvascular decompression for trigeminal neuralgia. <i>Journal of Neurosurgery</i> , 2017, 126, 1691-1697.	1.6	24
130	Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence. <i>Cancers</i> , 2021, 13, 2408.	3.7	24
131	Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143. <i>Journal of Clinical Oncology</i> , 2016, 34, 2014-2014.	1.6	24
132	Immunologic Consequences of Signal Transducers and Activators of Transcription 3 Activation in Human Squamous Cell Carcinoma. <i>Cancer Research</i> , 2010, 70, 6467-6476.	0.9	23
133	Heat shock protein-peptide complex in the treatment of glioblastoma. <i>Expert Review of Vaccines</i> , 2011, 10, 721-731.	4.4	23
134	Contrast-Enhanced CISS Imaging for Evaluation of Neurovascular Compression in Trigeminal Neuralgia: Improved Correlation with Symptoms and Prediction of Surgical Outcomes. <i>American Journal of Neuroradiology</i> , 2018, 39, 1724-1732.	2.4	23
135	Surgical Resection for Primary Central Nervous System Lymphoma: A Systematic Review. <i>World Neurosurgery</i> , 2019, 126, e1436-e1448.	1.3	23
136	Integrin $\beta 6$ signaling induces STAT3-TET3-mediated hydroxymethylation of genes critical for maintenance of glioma stem cells. <i>Oncogene</i> , 2020, 39, 2156-2169.	5.9	23
137	Stereotactic Radiosurgery for Spine Tumors: Review of Current Literature. <i>Stereotactic and Functional Neurosurgery</i> , 2010, 88, 315-321.	1.5	22
138	Predictors of Visual Outcome Following Surgical Resection of Medial Sphenoid Wing Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2012, 73, 321-326.	0.8	22
139	Stereotactic Radiosurgery of Cranial Arteriovenous Malformations and Dural Arteriovenous Fistulas. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 133-146.	1.7	22
140	Controversies in the Therapy of Brain Metastases: Shifting Paradigms in an Era of Effective Systemic Therapy and Longer-Term Survivorship. <i>Current Treatment Options in Oncology</i> , 2016, 17, 46.	3.0	22
141	Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa011.	0.7	22
142	Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma. <i>OncImmunity</i> , 2021, 10, 1956142.	4.6	22
143	Effectiveness of Repeat Glycerol Rhizotomy in Treating Recurrent Trigeminal Neuralgia. <i>Neurosurgery</i> , 2012, 70, 1125-1134.	1.1	21
144	Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell Lines. <i>PLoS ONE</i> , 2016, 11, e0150271.	2.5	21

#	ARTICLE	IF	CITATIONS
145	Long-term Treatment Response and Patient Outcomes for Vestibular Schwannoma Patients Treated with Hypofractionated Stereotactic Radiotherapy. <i>Frontiers in Oncology</i> , 2017, 7, 200.	2.8	21
146	The predictive value of serum myeloperoxidase for vasospasm in patients with aneurysmal subarachnoid hemorrhage. <i>Neurosurgical Review</i> , 2012, 35, 413-419.	2.4	20
147	The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. <i>Neurotherapeutics</i> , 2017, 14, 1049-1065.	4.4	20
148	The Molecular Basis and Pathophysiology of Trigeminal Neuralgia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3604.	4.1	20
149	Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 2567-2578.	7.0	20
150	ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma. <i>Neuro-Oncology</i> , 2022, 24, 888-900.	1.2	20
151	Metastatic Melanoma to the Brain: Surgery and Radiation Is Still the Standard of Care. <i>Current Treatment Options in Oncology</i> , 2013, 14, 264-279.	3.0	19
152	Progressive Low-Grade Glioma: Assessment of Prognostic Importance of Histologic Reassessment and MRI Findings. <i>World Neurosurgery</i> , 2017, 99, 751-757.	1.3	19
153	Adult immuno-oncology: using past failures to inform the future. <i>Neuro-Oncology</i> , 2020, 22, 1249-1261.	1.2	19
154	A Crowdsourced Consensus on Supratotal Resection Versus Gross Total Resection for Anatomically Distinct Primary Glioblastoma. <i>Neurosurgery</i> , 2021, 89, 712-719.	1.1	19
155	It takes two: potential therapies and insights involving microglia and macrophages in glioblastoma. <i>Neuroimmunology and Neuroinflammation</i> , 2018, 5, 42.	1.4	19
156	Immediate and Long-Term Outcomes of Microvascular Decompression for Mixed Trigeminal Neuralgia. <i>World Neurosurgery</i> , 2018, 117, e300-e307.	1.3	18
157	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 585-593.	7.0	18
158	Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac025.	0.7	18
159	Reversible Posterior Leukoencephalopathy Occurring during Resection of a Posterior Fossa Tumor: Case Report and Review of the Literature. <i>Neurosurgery</i> , 2001, 49, 1237-1240.	1.1	17
160	Immunotherapy Combined with Chemotherapy in the Treatment of Tumors. <i>Neurosurgery Clinics of North America</i> , 2010, 21, 187-194.	1.7	17
161	Clinical Trials with Immunotherapy for High-Grade Glioma. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 459-470.	1.7	17
162	A Systematic Analysis of the Reliability of Diffusion Tensor Imaging Tractography for Facial Nerve Imaging in Patients with Vestibular Schwannoma. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2016, 77, 314-318.	0.8	17

#	ARTICLE	IF	CITATIONS
163	InÂVivo Bioluminescence Tomography Center of Mass-Guided Conformal Irradiation. International Journal of Radiation Oncology Biology Physics, 2020, 106, 612-620.	0.8	17
164	Postoperative Anticoagulation in Patients with Mechanical Heart Valves Following Surgical Treatment of Subdural Hematomas. Neurocritical Care, 2013, 19, 90-94.	2.4	16
165	Genome-wide investigation of intragenic DNA methylation identifies <i>ZMIZ1</i> gene as a prognostic marker in glioblastoma and multiple cancer types. International Journal of Cancer, 2019, 145, 3425-3435.	5.1	16
166	CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548. Neuro-Oncology, 2021, 23, vi55-vi56.	1.2	16
167	Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors. Brain Tumor Research and Treatment, 2013, 1, 2.	1.0	15
168	Planning Evaluation of C-Arm Cone Beam CT Angiography for Target Delineation in Stereotactic Radiation Surgery of Brain Arteriovenous Malformations. International Journal of Radiation Oncology Biology Physics, 2014, 90, 430-437.	0.8	15
169	The role of checkpoints in the treatment of GBM. Journal of Neuro-Oncology, 2015, 123, 413-423.	2.9	15
170	CLEC5A expressed on myeloid cells as a M2 biomarker relates to immunosuppression and decreased survival in patients with glioma. Cancer Gene Therapy, 2020, 27, 669-679.	4.6	15
171	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15
172	Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma. Case Reports in Oncology, 2020, 13, 508-514.	0.7	15
173	Updated risk models demonstrate low risk of symptomatic radionecrosis following stereotactic radiosurgery for brain metastases. , 2019, 10, 32.		15
174	Biologic Principles of Immunotherapy for Malignant Gliomas. Neurosurgery Clinics of North America, 2010, 21, 1-16.	1.7	14
175	Combining immunotherapy with radiation for the treatment of glioblastoma. Journal of Neuro-Oncology, 2015, 123, 459-464.	2.9	14
176	Immunotherapy for Glioblastoma: Playing Chess, Not Checkers. Clinical Cancer Research, 2018, 24, 4059-4061.	7.0	14
177	Local recurrence patterns after postoperative stereotactic radiation surgery to resected brain metastases: A quantitative analysis to guide target delineation. Practical Radiation Oncology, 2018, 8, 388-396.	2.1	14
178	CyberKnife radiosurgical rhizotomy for the treatment of atypical trigeminal nerve pain. Neurosurgical Focus, 2007, 23, E8.	2.3	13
179	Current State of Immune-Based Therapies for Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e132-e139.	3.8	13
180	Risk of Developing Postoperative Deficits Based on Tumor Location after Surgical Resection of an Intracranial Meningioma. Journal of Neurological Surgery, Part B: Skull Base, 2019, 80, 059-066.	0.8	13

#	ARTICLE	IF	CITATIONS
181	Clinical Outcomes after Treatment of Germ Cell Tumors. <i>Neurosurgery Clinics of North America</i> , 2011, 22, 385-394.	1.7	12
182	A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain. <i>Case Reports in Oncological Medicine</i> , 2013, 2013, 1-4.	0.3	12
183	Patients undergoing surgery of intracranial metastases have different outcomes based on their primary pathology. <i>Neurological Research</i> , 2013, 35, 1059-1069.	1.3	12
184	GanetespiB radiosensitization for liver cancer therapy. <i>Cancer Biology and Therapy</i> , 2016, 17, 457-466.	3.4	12
185	Absence of Ischemic Injury after Sacrificing the Superior Petrosal Vein during Microvascular Decompression. <i>Operative Neurosurgery</i> , 2020, 18, 316-320.	0.8	12
186	Alternative Checkpoints as Targets for Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 126.	4.0	12
187	The Role of Myeloid Cells in GBM Immunosuppression. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	12
188	Utilization of the Nasoseptal Flap for Repair of Cerebrospinal Fluid Leak after Endoscopic Endonasal Approach for Resection of Pituitary Tumors. <i>Brain Tumor Research and Treatment</i> , 2019, 7, 10.	1.0	11
189	Synergy between glutamate modulation and anti-“programmed cell death protein 1 immunotherapy for glioblastoma. <i>Journal of Neurosurgery</i> , 2022, 136, 379-388.	1.6	11
190	Quantitative Bioluminescence Tomography-Guided Conformal Irradiation for Preclinical Radiation Research. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1310-1321.	0.8	11
191	PD-1+ Monocytes Mediate Cerebral Vasospasm Following Subarachnoid Hemorrhage. <i>Neurosurgery</i> , 2021, 88, 855-863.	1.1	11
192	Current State of Immune-Based Therapies for Glioblastoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e132-e139.	3.8	11
193	Glycerol rhizotomy via a retrosigmoid approach as an alternative treatment for trigeminal neuralgia. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 2454-2456.	1.4	10
194	Technical note: Orbitozygomatic craniotomy using an ultrasonic osteotome for precise osteotomies. <i>Clinical Neurology and Neurosurgery</i> , 2015, 134, 24-27.	1.4	10
195	The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma—Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 50.	4.2	10
196	PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 74-85.	1.7	10
197	Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2017-2017.	1.6	10
198	Real-Time Imaging with the O-Arm for Skull Base Applications: A Cadaveric Feasibility Study. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2012, 73, 293-301.	0.8	9

#	ARTICLE	IF	CITATIONS
199	Long-term Outcomes With Planned Multistage Reduced Dose Repeat Stereotactic Radiosurgery for Treatment of Inoperable High-Grade Arteriovenous Malformations: An Observational Retrospective Cohort Study. <i>Neurosurgery</i> , 2017, 81, 136-146.	1.1	9
200	Tumor-Treating Field Arrays Do Not Reduce Target Volume Coverage for Glioblastoma Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2020, 5, 62-69.	1.2	9
201	New Prospects for Molecular Targets for Chordomas. <i>Neurosurgery Clinics of North America</i> , 2020, 31, 289-300.	1.7	9
202	Updated safety phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2512-2512.	1.6	9
203	Advances in Immunotherapies for Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 1-10.	4.2	9
204	Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series. <i>Radiation Oncology</i> , 2011, 6, 25.	2.7	8
205	Integrative analysis of DNA methylation suggests down-regulation of oncogenic pathways and reduced somatic mutation rates in survival outliers of glioblastoma. <i>Acta Neuropathologica Communications</i> , 2019, 7, 88.	5.2	8
206	The Effects of Postoperative Neurological Deficits on Survival in Patients With Single Brain Metastasis. <i>Operative Neurosurgery</i> , 2020, 19, 628-634.	0.8	8
207	Scalp Invasion by Atypical or Anaplastic Meningioma Is a Risk Factor for Development of Systemic Metastasis. <i>World Neurosurgery</i> , 2020, 142, e133-e139.	1.3	8
208	Enhancing proteasomal processing improves survival for a peptide vaccine used to treat glioblastoma. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	8
209	Development of new brain metastases in triple negative breast cancer. <i>Journal of Neuro-Oncology</i> , 2021, 152, 333-338.	2.9	8
210	Newly diagnosed glioblastoma patients treated with an autologous heat shock protein peptide vaccine: PD-L1 expression and response to therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2011-2011.	1.6	8
211	Outcomes of Metastatic Brain Lesions Treated with Radioactive Cs-131 Seeds after Surgery: Experience from One Institution. <i>Cureus</i> , 2018, 10, e3075.	0.5	8
212	A Virtual Frame System for Stereotactic Radiosurgery Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1244-1249.	0.8	7
213	Survival and Recurrence for Patients Undergoing Surgery of Skull Base Intracranial Metastases. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2013, 74, 228-235.	0.8	7
214	Identifying Better Surgical Candidates Among Recursive Partitioning Analysis Class 2 Patients who Underwent Surgery for Intracranial Metastases. <i>World Neurosurgery</i> , 2014, 82, e267-e275.	1.3	7
215	Laser speckle imaging to improve clinical outcomes for patients with trigeminal neuralgia undergoing radiofrequency thermocoagulation. <i>Journal of Neurosurgery</i> , 2016, 124, 422-428.	1.6	7
216	Association Between Radiofrequency Rhizotomy Parameters and Duration of Pain Relief in Trigeminal Neuralgia Patients with Recurrent Pain. <i>World Neurosurgery</i> , 2019, 129, e128-e133.	1.3	7

#	ARTICLE	IF	CITATIONS
217	Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. <i>Journal of Neuro-Oncology</i> , 2021, 152, 125-134.	2.9	7
218	Sustained localized delivery of immunotherapy to lymph nodes reverses immunosuppression and increases long-term survival in murine glioblastoma. <i>Oncolimmunology</i> , 2021, 10, 1940673.	4.6	7
219	The safety and efficacy of dexamethasone in the perioperative management of glioma patients. <i>Journal of Neurosurgery</i> , 2022, 136, 1062-1069.	1.6	7
220	Adjuvant radiotherapy and outcomes of presumed hemorrhagic melanoma brain metastases without malignant cells. , 2018, 9, 146.		7
221	PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors. <i>Cureus</i> , 2019, 11, e6352.	0.5	7
222	Extracranial Abscopal Responses after Radiation Therapy for Intracranial Metastases: A Review of the Clinical Literature and Commentary on Mechanism. <i>Cureus</i> , 2019, 11, e4207.	0.5	7
223	The future of cancer immunotherapy for brain tumors: a collaborative workshop. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	7
224	IMCT-03SAFETY AND ACTIVITY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE-143. <i>Neuro-Oncology</i> , 2015, 17, v107.3-v107.	1.2	6
225	High-Resolution MRI Findings following Trigeminal Rhizotomy. <i>American Journal of Neuroradiology</i> , 2016, 37, 1920-1924.	2.4	6
226	ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB,) Tj ETQq0 0 0 rgBT /Overl <i>Neuro-Oncology</i> , 2018, 20, vi10-vi10.	1.2	6
227	Oligometastatic Adenocarcinoma of the Lung: A Therapeutic Opportunity for Long-Term Survival. <i>Cureus</i> , 2015, 7, e409.	0.5	6
228	Delivery of stereotactic radiosurgery: a cross-platform comparison. <i>Neurological Research</i> , 2011, 33, 787-791.	1.3	5
229	Selective cerebral hypothermia induced via hypothermic retrograde jugular vein saline flush in a porcine model. <i>Neurological Research</i> , 2014, 36, 897-902.	1.3	5
230	Neurocytoma of the Spinal Cord. <i>Neurosurgery Clinics of North America</i> , 2015, 26, 109-115.	1.7	5
231	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited â€œ Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e709-e710.	10.7	5
232	Reply to Haffner et al.: DNA hypomethylation renders tumors more immunogenic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8583-E8584.	7.1	5
233	GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS2579-TPS2579.	1.6	5
234	Is There a Role for Immunotherapy in Central Nervous System Cancers?. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 237-252.	2.2	5

#	ARTICLE	IF	CITATIONS
235	The roles of thermal and mechanical stress in focused ultrasound-mediated immunomodulation and immunotherapy for central nervous system tumors. <i>Journal of Neuro-Oncology</i> , 2022, 157, 221-236.	2.9	5
236	Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-5.	0.3	4
237	Postoperative sinonasal morbidity in sellar reconstruction: mucosal autograft versus acellular dermal allograft. <i>International Forum of Allergy and Rhinology</i> , 2017, 7, 1178-1185.	2.8	4
238	Deferred Radiotherapy After Debulking of Non-functioning Pituitary Macroadenomas: Clinical Outcomes. <i>Frontiers in Oncology</i> , 2019, 8, 660.	2.8	4
239	A Dose-Response Model of Local Tumor Control Probability After Stereotactic Radiosurgery for Brain Metastases Resection Cavities. <i>Advances in Radiation Oncology</i> , 2020, 5, 840-849.	1.2	4
240	Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2080-TPS2080.	1.6	4
241	Retrosigmoid approach for glycerin rhizotomy in the treatment of trigeminal neuralgia without overt arterial compression: updated case series. <i>Journal of Neurosurgery</i> , 2020, 132, 1227-1233.	1.6	4
242	Quality of Life and Role of Palliative and Supportive Care for Patients With Brain Metastases and Caregivers: A Review. <i>Frontiers in Neurology</i> , 2022, 13, 806344.	2.4	4
243	Learning-based analysis of amide proton transfer-weighted MRI to identify true progression in glioma patients. <i>NeuroImage: Clinical</i> , 2022, , 103121.	2.7	4
244	Discussion on. <i>Journal of Craniofacial Surgery</i> , 2016, 27, 1568-1570.	0.7	3
245	Spontaneous Intracranial Hypotension after Vestibular Schwannoma Resection Due to an Unexpected Pathology: Tarlov Cysts. <i>Cureus</i> , 2017, 9, e1261.	0.5	3
246	ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. <i>Neuro-Oncology</i> , 2019, 21, vi12-vi12.	1.2	3
247	Cottonoid Sliders: A Simple and Cost-Effective Tool for Retractorless Intracranial Surgery. <i>Operative Neurosurgery</i> , 2020, 19, E428-E431.	0.8	3
248	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab035.	0.7	3
249	Bone Cement Internal Auditory Canal Reconstruction to Reduce CSF Leak After Vestibular Schwannoma Retrosigmoid Approach. <i>Otology and Neurotology</i> , 2021, 42, e1101-e1105.	1.3	3
250	Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy. <i>Journal of Neurosurgery</i> , 2022, 136, 56-66.	1.6	3
251	Emerging Technologies for Non-invasive Monitoring of Treatment Response to Immunotherapy for Brain Tumors. <i>NeuroMolecular Medicine</i> , 2022, 24, 74-87.	3.4	3
252	The Challenges and Future of Immunotherapy for Gliomas. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 371-378.	2.0	3

#	ARTICLE	IF	CITATIONS
253	Abstract 1736: The combination of CXCR4 and checkpoint receptor inhibition improves survival in an orthotopic murine glioma model. , 2018, , .		3
254	Quantitative Bioluminescence Tomography for In Vivo Volumetric-Guided Radiotherapy. Methods in Molecular Biology, 2022, 2393, 701-731.	0.9	3
255	Clinical features and surgical outcomes of intracranial and spinal cord subependymomas. Journal of Neurosurgery, 2022, 137, 931-942.	1.6	3
256	CyberKnife Radiosurgery for Extremity Schwannomas: Technical Note and Case Report. Stereotactic and Functional Neurosurgery, 2006, 84, 60-63.	1.5	2
257	Metastatic Extrapulmonary Small Cell Carcinoma to the Cerebellopontine Angle: A Case Report and Review of the Literature. Case Reports in Oncological Medicine, 2015, 2015, 1-6.	0.3	2
258	Timely stereotactic body radiotherapy (SBRT) for spine metastases using a rapidly deployable automated planning algorithm. SpringerPlus, 2016, 5, 1337.	1.2	2
259	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2021, 39, TPS2074-TPS2074.	1.6	2
260	Impact of international research fellows in neurosurgery: results from a single academic center. Journal of Neurosurgery, 2022, 136, 295-305.	1.6	2
261	Stereotactic radiosurgery using CT cisternography and non-isocentric planning for the treatment of trigeminal neuralgia. Computer Aided Surgery, 2006, 11, 11-20.	1.8	2
262	Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).. Journal of Clinical Oncology, 2015, 33, TPS2077-TPS2077.	1.6	2
263	Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab ± ipilimumab: CheckMate 143.. Journal of Clinical Oncology, 2017, 35, 2001-2001.	1.6	2
264	Why is immunotherapy for glioblastoma “Lagging”. Oncotarget, 2019, 10, 1228-1229.	1.8	2
265	Neurosurgery concepts: Key perspectives on endoscopic versus microscopic resection for pituitary adenomas, surgical decision-making in tuberculum sellae meningiomas, optic nerve mobilization during resection of craniopharyngiomas, and evaluation of headache and quality of life after endoscopic transphenoidal surgery for pituitary adenomas. , 2017, 8, 52.		2
266	In Vivo Evaluation of Near-Infrared Fluorescent Probe for TIM3 Targeting in Mouse Glioma. Molecular Imaging and Biology, 2021, , 1.	2.6	2
267	Calcium-Related Gene Signatures May Predict Prognosis and Level of Immunosuppression in Gliomas. Frontiers in Oncology, 2022, 12, .	2.8	2
268	Neurosurgery concepts: Key perspectives on dendritic cell vaccines, metastatic tumor treatment, and radiosurgery. , 2015, 6, 6.		1
269	Introduction: brain tumor immunotherapy. Journal of Neuro-Oncology, 2015, 123, 321-322.	2.9	1
270	Immunotherapy for glioblastoma: are we finally getting closer?. Neuro-Oncology, 2015, 17, 771-772.	1.2	1

#	ARTICLE	IF	CITATIONS
271	TMOD-37. IN VIVO SYNERGISTIC EFFECT OF CHECKPOINT BLOCKADE AND RADIATION THERAPY AGAINST CHORDOMAS IN A HUMANIZED MOUSE MODEL. <i>Neuro-Oncology</i> , 2018, 20, vi276-vi276.	1.2	1
272	In Reply to Yilmaz etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 998-999.	0.8	1
273	IMMU-18. IMMUNOGENOMIC RESPONDER PHENOTYPE FROM A PHASE I TRIAL OF ANTI-LAG3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM. <i>Neuro-Oncology</i> , 2019, 21, vi122-vi123.	1.2	1
274	Chronic Lymphocytic Leukemia Resulting in Hemorrhagic Brain Masses After Sepsis. <i>Neurohospitalist</i> , The, 2020, 10, 64-68.	0.8	1
275	Understanding innate immune response in glioblastoma in search of a way forward. <i>Neuro-Oncology</i> , 2020, 22, 444-445.	1.2	1
276	In Reply: Absence of Ischemic Injury After Sacrificing the Superior Petrosal Vein During Microvascular Decompression. <i>Operative Neurosurgery</i> , 2021, 20, E260-E260.	0.8	1
277	Risk of Developing Postoperative Deficits Based on Tumor Location after Surgical Resection of an Intracranial Meningioma. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2018, 79, S1-S188.	0.8	1
278	Endoscopic Harvest and Transposition of Vascularized Pericranial Flap for Minimal Access Open and Endoscopic Skull Base Repair: Technical Notes and Case Illustration. <i>Skull Base</i> , 2011, 21, .	0.4	1
279	Neurosurgery concepts: Key perspectives on imaging characteristics of spinal metastases, surgery for low back pain, anesthesia for disc surgery, and laminectomy versus laminectomy and fusion for lumbar spondylolisthesis. , 2017, 8, 9.		1
280	Issues to Consider in Designing Immunotherapy Clinical Trials for Glioblastoma Management. <i>Journal of Cancer Therapy</i> , 2016, 07, 573-585.	0.4	1
281	Abstract B165: Investigating in vivo synergistic effect of checkpoint blockade and radiation therapy against chordomas in a humanized mouse model. , 2019, , .		1
282	NCOG-32. THE SAFETY AND EFFICACY OF DEXAMETHASONE IN THE MANAGEMENT OF GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii136-ii136.	1.2	1
283	IMMU-13. EFFICACY OF CXCR6 BLOCKADE AS A POTENTIATOR OF ANTI-PD-1 THERAPY FOR THE TREATMENT OF GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii107-ii107.	1.2	1
284	Case Series in the Utility of Invasive Blood Pressure Monitoring in Microvascular Decompression. <i>Operative Neurosurgery</i> , 2022, 22, 262-268.	0.8	1
285	Internal neurectomy versus intraoperative glycerin rhizotomy for trigeminal neuralgia. <i>Journal of Neurosurgery</i> , 2023, 138, 270-275.	1.6	1
286	Preface. <i>Neurosurgery Clinics of North America</i> , 2010, 21, xv.	1.7	0
287	Perspectives on key articles in neurosurgery. , 2012, 3, 58.		0
288	Management of Cerebral Brain Metastasis. <i>Current Surgery Reports</i> , 2014, 2, 1.	0.9	0

#	ARTICLE	IF	CITATIONS
289	NIMG-16PSEUDOPROGRESSION AND IMMUNOTHERAPY IN GLIOBLASTOMA: A CASE SERIES FROM COHORT 1 OF CHECKMATE-143 (NCT02017717). <i>Neuro-Oncology</i> , 2015, 17, v156.3-v156.	1.2	0
290	NIMG-17CENTRAL NEUROPATHOLOGY REVIEW TO ASSIST IN THE EVALUATION OF IMMUNE-RELATED TREATMENT CHANGES VERSUS DISEASE PROGRESSION IN CHECKMATE-143. <i>Neuro-Oncology</i> , 2015, 17, v156.4-v157.	1.2	0
291	NIMG-18EVALUATING TUMOR PROGRESSION AND IMMUNOLOGIC REACTIONS DURING IMMUNOTHERAPY: NEUROIMAGING OBSERVATIONS FROM A MULTICENTER STUDY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA (CHECKMATE-143). <i>Neuro-Oncology</i> , 2015, 17, v157.1-v157.	1.2	0
292	Immunotherapy for Glioblastoma. <i>Journal of Clinical & Cellular Immunology</i> , 2016, 7, .	1.5	0
293	IMST-58. MODULATING THE MYELOID COMPARTMENT TO POTENTIATE ANTI-PD1 MEDIATED IMMUNOTHERAPY AGAINST GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, vi99-vi99.	1.2	0
294	Preface. <i>Neurosurgery Clinics of North America</i> , 2016, 27, ix.	1.7	0
295	Nontyphoidal Salmonellosis, Human Immunodeficiency Virus Infection, and Ischemic Stroke. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw104.	0.9	0
296	ATIM-21. UPDATED RESULTS OF A PHASE I TRIAL OF ANTI-LAG-3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM. <i>Neuro-Oncology</i> , 2018, 20, vi5-vi5.	1.2	0
297	RTHP-13. TUMOR-TREATING FIELDS THERAPY IS COMPATIBLE WITH STANDARD CHEMORADIOTHERAPY FOR GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi228-vi228.	1.2	0
298	EXTH-03. LOCAL ONCOLYTIC ADENOVIRUS TREATMENT AFFECTS BOTH THE INNATE AND ADAPTIVE ARMS OF THE IMMUNE SYSTEM AND PROVIDES AN AVENUE FOR ENHANCING IMMUNOTHERAPIES FOR GBM. <i>Neuro-Oncology</i> , 2018, 20, vi85-vi85.	1.2	0
299	Commentary: Does Stereotactic Radiosurgery Have a Role in the Management of Patients Presenting With 4 or More Brain Metastases?. <i>Neurosurgery</i> , 2019, 84, 567-568.	1.1	0
300	Thalamic gliomas: Advances in the surgical management. , 2019, , 117-135.		0
301	Assessing the Effectiveness of Systemic Therapy after Stereotactic Radiosurgery on Cancer Recurrence and All-Cause Mortality. <i>World Neurosurgery</i> , 2019, 129, e572-e581.	1.3	0
302	Bespoke immunotherapy: how close are we?. <i>Neuro-Oncology</i> , 2019, 21, 289-290.	1.2	0
303	TMIC-14. PD-L1 EXPRESSION IS NEGATIVELY CORRELATED TO OUTCOMES IN PATIENTS WITH MGMT METHYLATED PROMOTERS IN GBM. <i>Neuro-Oncology</i> , 2019, 21, vi250-vi250.	1.2	0
304	SURG-16. SUPRATOTAL VERSUS GROSS TOTAL RESECTION OF GLIOBLASTOMA: A SYSTEMATIC REVIEW. <i>Neuro-Oncology</i> , 2019, 21, vi243-vi243.	1.2	0
305	Approach to the meningioma patient. , 2021, , 118-135.		0
306	OUP accepted manuscript. <i>Neuro-Oncology</i> , 2021, , .	1.2	0

#	ARTICLE	IF	CITATIONS
307	Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. <i>Neuro-Oncology</i> , 2021, 23, 506-507.	1.2	0
308	RADI-23. Exploring the optimal timing of routine initial surveillance MRI following treatment of brain metastases with stereotactic radiosurgery: a comparison of two approaches. <i>Neuro-Oncology Advances</i> , 2021, 3, iii23-iii23.	0.7	0
309	The utility of MR enhancement as a noninvasive predictor for high-grade histology in patients with progressive low-grade gliomas: Is histology needed to guide therapy?. <i>Journal of Clinical Oncology</i> , 2014, 32, 2098-2098.	1.6	0
310	Abstract A046: Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM). , 2016, , .		0
311	History of Trigeminal Neuralgia. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2018, , 1-31.	0.1	0
312	The Relevance of Simpson Grade Resections in the Modern Neurosurgical Treatment of World Health Organization Grades 1, 2, and 3 Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2018, 79, S1-S188.	0.8	0
313	Abstract 5874: Targeting DDX3 in medulloblastoma by RK-33. , 2018, , .		0
314	Glycerol Rhizotomy for the Management of Tumor-Associated Trigeminal Neuralgia. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2020, 81, .	0.8	0
315	Abstract 4491: Characterizing long non-coding RNA expression of tumor-infiltrating lymphocytes across solid cancers. , 2020, , .		0
316	Immunotherapy and Radiosurgery. , 2020, , 423-436.		0
317	Anticoagulation for Cerebral Venous Sinus Thrombosis after Posterior Fossa Schwannoma Surgery: Worth the Risk?. , 2020, 81, .		0
318	Fire in the Smoke: Battling Brain Tumors. <i>Cerebrum: the Dana Forum on Brain Science</i> , 2018, 2018, .	0.1	0
319	RTID-11. GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii195-ii196.	1.2	0
320	SURG-21. A CROWDSOURCED CONSENSUS ON SUPRATOTAL RESECTION VERSUS GROSS TOTAL RESECTION FOR ANATOMICALLY DISTINCT PRIMARY GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii207-ii208.	1.2	0
321	NCOG-25. EFFICACY OF ANTICONVULSANT THERAPY IN GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii134-ii134.	1.2	0
322	IMMU-27. SINGLE CELL RNA-SEQUENCING IDENTIFIES NOVEL BONE MARROW DERIVED MYELOID CELLS IN GLIOBLASTOMA ASSOCIATED WITH TUMOR AGGRESSION. <i>Neuro-Oncology</i> , 2020, 22, ii110-ii110.	1.2	0
323	COVID-31. THE STATE OF NEURO-ONCOLOGY DURING THE COVID-19 PANDEMIC: A WORLDWIDE ASSESSMENT. <i>Neuro-Oncology</i> , 2020, 22, ii27-ii27.	1.2	0
324	NCOG-05. MANAGEMENT OF BRAIN METASTASIS IN TRIPLE NEGATIVE BREAST CANCER. <i>Neuro-Oncology</i> , 2020, 22, ii130-ii130.	1.2	0

#	ARTICLE	IF	CITATIONS
325	Introduction. Immunology of neurosurgical diseases. Neurosurgical Focus, 2022, 52, E1.	2.3	0
326	Cranioplasty With Customized Craniofacial Implants and Intraoperative Resizing for Single-Stage Reconstruction Following Oncologic Resection of Skull Neoplasms. Journal of Craniofacial Surgery, 2022, 33, 1641-1647.	0.7	0
327	Applying Synthetic Biology with Rational Design to Nature's Greatest Challenges: Bioengineering Immunotherapeutics for the Treatment of Glioblastoma. Immuno, 2022, 2, 40-51.	1.5	0
328	Diversity within the Neurosurgical Oncology Workforce in the United States: A Cross-Sectional Study with Proposed Strategies to Pave the Path Forward. Neuro-Oncology, 0, , .	1.2	0